abstract: Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer (astounding figures)

Economic impact of paclitaxel shortage in patients with newly diagnosed ovarian cancer - NCBI

Abstract

OBJECTIVE:

To determine the potential economic impact of a paclitaxel drug shortage in patients with newly diagnosed, untreated ovarian cancer.

RESULTS:

...... A drug shortage that affects approximately 50% of women initiating chemotherapy is expected to impact 779 women and cost third party payers an additional $8,699,872 monthly.

CONCLUSIONS:

Our model indicates that chemotherapy drug shortages can have a significant negative impact on the average cost of primary treatment for ovarian cancer and have the potential to negatively impact health system costs.